These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31638799)

  • 1. Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity.
    Kawai J; Toki T; Ota M; Inoue H; Takata Y; Asahi T; Suzuki M; Shimada T; Ono K; Suzuki K; Takaishi S; Ohki H; Matsui S; Tsutsumi S; Hirota Y; Nakayama K
    J Med Chem; 2019 Nov; 62(22):10204-10220. PubMed ID: 31638799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer.
    Lee J; Chen X; Wang Y; Nishimura T; Li M; Ishikawa S; Daikoku T; Kawai J; Tojo A; Gotoh N
    Biochem Biophys Res Commun; 2021 Dec; 584():7-14. PubMed ID: 34753066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Ju HQ; Lu YX; Chen DL; Zuo ZX; Liu ZX; Wu QN; Mo HY; Wang ZX; Wang DS; Pu HY; Zeng ZL; Li B; Xie D; Huang P; Hung MC; Chiao PJ; Xu RH
    J Natl Cancer Inst; 2019 Jun; 111(6):584-596. PubMed ID: 30534944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine Derivatives Reveal an Allosteric Binding Site in Methylenetetrahydrofolate Dehydrogenase 2 (MTHFD2).
    Lee LC; Peng YH; Chang HH; Hsu T; Lu CT; Huang CH; Hsueh CC; Kung FC; Kuo CC; Jiaang WT; Wu SY
    J Med Chem; 2021 Aug; 64(15):11288-11301. PubMed ID: 34337952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
    Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
    Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
    Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
    Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selectivity analysis of diaminopyrimidine-based inhibitors of MTHFD1, MTHFD2 and MTHFD2L.
    Jha V; Eriksson LA
    Sci Rep; 2024 Sep; 14(1):21073. PubMed ID: 39256448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy.
    Yang C; Zhang J; Liao M; Yang Y; Wang Y; Yuan Y; Ouyang L
    Drug Discov Today; 2021 Mar; 26(3):817-825. PubMed ID: 33316375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.
    Scott JS; Moss TA; Balazs A; Barlaam B; Breed J; Carbajo RJ; Chiarparin E; Davey PRJ; Delpuech O; Fawell S; Fisher DI; Gagrica S; Gangl ET; Grebe T; Greenwood RD; Hande S; Hatoum-Mokdad H; Herlihy K; Hughes S; Hunt TA; Huynh H; Janbon SLM; Johnson T; Kavanagh S; Klinowska T; Lawson M; Lister AS; Marden S; McGinnity DF; Morrow CJ; Nissink JWM; O'Donovan DH; Peng B; Polanski R; Stead DS; Stokes S; Thakur K; Throner SR; Tucker MJ; Varnes J; Wang H; Wilson DM; Wu D; Wu Y; Yang B; Yang W
    J Med Chem; 2020 Dec; 63(23):14530-14559. PubMed ID: 32910656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions.
    Mo HY; Wang RB; Ma MY; Zhang Y; Li XY; Wen WR; Han Y; Tian T
    Redox Rep; 2024 Dec; 29(1):2345455. PubMed ID: 38723197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
    Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
    Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD.
    Fu C; Sikandar A; Donner J; Zaburannyi N; Herrmann J; Reck M; Wagner-Döbler I; Koehnke J; Müller R
    Nat Commun; 2017 Nov; 8(1):1529. PubMed ID: 29142318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
    Leger PR; Hu DX; Biannic B; Bui M; Han X; Karbarz E; Maung J; Okano A; Osipov M; Shibuya GM; Young K; Higgs C; Abraham B; Bradford D; Cho C; Colas C; Jacobson S; Ohol YM; Pookot D; Rana P; Sanchez J; Shah N; Sun M; Wong S; Brockstedt DG; Kassner PD; Schwarz JB; Wustrow DJ
    J Med Chem; 2020 May; 63(10):5398-5420. PubMed ID: 32302140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of MTHFD2 in MCF-7 Breast Cancer Cells Increases Glycolysis, Dependency on Exogenous Glycine, and Sensitivity to Folate Depletion.
    Koufaris C; Gallage S; Yang T; Lau CH; Valbuena GN; Keun HC
    J Proteome Res; 2016 Aug; 15(8):2618-25. PubMed ID: 27315223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
    Lapierre JM; Eathiraj S; Vensel D; Liu Y; Bull CO; Cornell-Kennon S; Iimura S; Kelleher EW; Kizer DE; Koerner S; Makhija S; Matsuda A; Moussa M; Namdev N; Savage RE; Szwaya J; Volckova E; Westlund N; Wu H; Schwartz B
    J Med Chem; 2016 Jul; 59(13):6455-69. PubMed ID: 27305487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
    Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro.
    Baker JR; Gilbert J; Paula S; Zhu X; Sakoff JA; McCluskey A
    ChemMedChem; 2018 Jul; 13(14):1447-1458. PubMed ID: 29771007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.